Evidence map›Paper›PMID 36054524›Full record

ArticleBrain pathology (Zurich, Switzerland)2023

Pathological tau signatures and nuclear alterations in neurons, astrocytes and microglia in Alzheimer's disease, progressive supranuclear palsy, and dementia with Lewy bodies.

Mauro Montalbano, Lajja Majmundar, Urmi Sengupta, Leiana Fung, Rakez Kayed

Open access · goldAbstract read
In one paragraph

Article in Brain pathology (Zurich, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
3.8field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 35 citations in OpenAlex.

  1. Article
  2. Exploring the PLD1-tau interaction in Frontotemporal Dementia.bioRxiv : the preprint server for biology · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Neuroinflammation in Alzheimer disease.Nature reviews. Immunology · 2025
    Review
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Mauro MontalbanoMitchell Center for Neurodegenerative Disorders, University of Texas Medical Branch, UTMB, Galveston, Texas, USA.
Lajja MajmundarSchool of Medicine, University of Texas Medical Branch, UTMB, Galveston, Texas, USA.
Urmi SenguptaMitchell Center for Neurodegenerative Disorders, University of Texas Medical Branch, UTMB, Galveston, Texas, USA.
Leiana FungMitchell Center for Neurodegenerative Disorders, University of Texas Medical Branch, UTMB, Galveston, Texas, USA.
Rakez KayedMitchell Center for Neurodegenerative Disorders, University of Texas Medical Branch, UTMB, Galveston, Texas, USA.ORCID 0000-0001-6216-8640
The University of Texas Medical Branch at Galveston · US

Funding

Interdisciplinary Research Network on Biologically Active Tau Aggregate Polymorphs from Alzheimer's Disease and Related DementiasU24AG072458 · NIA · UNIVERSITY OF TEXAS MED BR GALVESTON · PI EISENBERG, DAVID, KAYED, RAKEZ · 2021 to 2025
$7.8M
Formation and Propagation of Tau Oligomeric Strains in Alzheimer's DiseaseR01AG054025 · NIA · UNIVERSITY OF TEXAS MED BR GALVESTON · PI Rakez Kayed · 2016 to 2026
$5.8M
The Role of Ubiquitination in Tau Oligomers PathogenesisR01AG077253 · NIA · UNIVERSITY OF TEXAS MED BR GALVESTON · PI Rakez Kayed, Yingxin Zhao · 2022 to 2026
$3.7M
Calcineurin Mediates the Synergistic Toxicity of Tau and Aβ OligomersRF1AG060718 · NIA · UNIVERSITY OF TEXAS MED BR GALVESTON · PI KAYED, RAKEZ, TAGLIALATELA, GIULIO · 2019 to 2019
$3.5M
Tau in the Eye and BrainRF1AG055771 · NIA · UNIVERSITY OF TEXAS MED BR GALVESTON · PI KAYED, RAKEZ, ZHANG, WENBO · 2017 to 2017
$2.7M
Immunotherapy Targeting Tau Aggregate PolymorphsRF1AG077484 · NIA · UNIVERSITY OF TEXAS MED BR GALVESTON · PI KAYED, RAKEZ · 2022 to 2022
$2.0M
Predoctoral and Postdoctoral Training in Alzheimer's PathophysiologyT32AG067952 · NIA · UNIVERSITY OF TEXAS MED BR GALVESTON · PI KAYED, RAKEZ · 2021 to 2025
$1.5M
Calcineurin Mediates the Synergistic Toxicity of Tau and Aβ OligomersR01AG060718 · NIA · UNIVERSITY OF TEXAS MED BR GALVESTON · PI KAYED, RAKEZ, TAGLIALATELA, GIULIO · 2019 to 2019
$39k
Alzheimer's Association AARF-21-720991NIA NIH HHS R01 AG054025NIA NIH HHS R01 AG060718NIA NIH HHS R01 AG077253NIA NIH HHS RF1 AG055771NIA NIH HHS RF1 AG060718NIA NIH HHS RF1 AG077484NIA NIH HHS T32 AG067952NIA NIH HHS U24 AG072458
6 · The paper itself

Abstract

Accumulation of pathological tau aggregates is a prominent feature in tauopathies that leads during the course of the diseases to neuronal dysfunction before and cell death after. Microglia and astrocytes have been described as playing important roles in synaptic spreading of toxic tau in several neurodegenerative diseases (NDs). Here, we have investigated the immunological and biochemical properties of aggregated tau species in different brain cell types in tau-induced neurodegenerative diseases such as Alzheimer's disease (AD), progressive supranuclear palsy (PSP), and dementia with Lewy bodies (DLB). Additionally, we examined nuclear size, nuclear density, and chromatin compaction in neuronal and glial cells from diseased brain tissues. Microscopic-histological examination was performed using in-house mouse monoclonal antibodies for toxic tau conformers (TTC-M1 and TTC-M2) and tau oligomers (TOMA1-4). By immunohistochemistry and co-immunofluorescence assays using TOMA/TTC-Ms and cell-type specific markers for neurons, astrocytes, and microglia, we observed that TOMA/TTC-Ms were immunoreactive to diverse tau species in different cell types. Analysis of colocalization coefficients indicated an increased pathological tau deposition mainly in the neurons. Western blot analysis of brain homogenates using TOMA/TTC-Ms revealed distinct patterns of tau aggregation in each disease, suggesting that TOMA/TTC-Ms can distinguish between different tau aggregates present in different tauopathies. Additionally, using DAPI staining, we observed that neuronal and astrocytic nuclei had significantly greater nuclear area and increased chromatin compaction in AD cortices compared to non-demented controls. In contrast, reduction in nuclear density/area and more relaxed chromatin was noticed in DLB neurons, astrocytes and microglia and PSP astrocytes and microglia. Cell-type specific tropism of toxic tau species in tauopathies will provide a greater understanding of the involvement of different brain cell types in tau pathology. In this study, we observed that each disease presented cell-type specific nuclear phenotype and tau deposition pattern.

Indexed as

Alzheimer DiseaseLewy Body DiseaseNeurodegenerative DiseasesSupranuclear Palsy, ProgressiveTauopathiesAnimalsAstrocytesBrainMiceMicrogliaNeuronstau Proteinstau Proteinsglianeuronnucleitau conformerstauopathies

Identifiers

PMID36054524
PMCPMC9836371
OpenAlexW4292869241

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.